Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cardiff Oncology Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $121.00K Beat $92.86K Estimate

Author: Benzinga Newsdesk | July 29, 2025 03:14pm
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 19.23 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $121.00 thousand which beat the analyst consensus estimate of $92.86 thousand by 30.31 percent. This is a 25.77 percent decrease over sales of $163.00 thousand the same period last year.

Posted In: CRDF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist